Non-alcoholic steatohepatitis research hub
10 indexed studies · 8 currently recruiting
- recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
A Randomised, Open-Label, Single-Centre, Study to Evaluate the Bioequivalence of Lanifibranor
This study is looking at a new medicine called Lanifibranor for a liver condition called non-alcoholic steatohepatitis (NASH). It's an early-stage study to see if a new version of the medicine works the same way in the body as an older version.
France - active not recruitingPHASE3
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
This study is looking at a medicine called semaglutide for a liver condition called non-alcoholic steatohepatitis (NASH). Participants will receive either semaglutide or a dummy medicine. It's a long study, lasting about 5 years, with regular clinic visits.
United States · Argentina · Australia - recruitingHuman Pharmacology (Phase I)- Other
MK-7480 Multiple Ascending Dose Study in Healthy Participants
This study is testing a new medicine, MK-7480, in healthy men. It aims to see how safe the medicine is and how the body handles different doses. This is a very early stage of research, paving the way for potential future treatments for liver disease.
Belgium - recruitingHuman Pharmacology (Phase I)- First administration to humans
MK-7480 Single Ascending Dose Study in Healthy Participants
This study is testing a new medicine, MK-7480, in healthy men for the very first time. It's looking to see how safe the medicine is and what it does in the body. This is an early step in finding new treatments for a liver condition called non-alcoholic steatohepatitis (NASH).
Belgium - recruitingTherapeutic exploratory (Phase II)
A Phase 2b Randomized, Double-Blind Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Precirrhotic Nonalcoholic Steatohepatitis
This study is looking at a new medicine called efinopegdutide for adults with a liver condition called non-alcoholic steatohepatitis (NASH). It compares this new medicine with another one called semaglutide or a dummy treatment to see if it improves the liver and is safe.
Spain · Belgium · Austria - recruitingPHASE2
Soluble Fibre Supplementation in NAFLD
This study, called FIND, is looking at whether a special fibre supplement can help children aged 8-17 with fatty liver disease. Participants will take either the fibre or a dummy pill, and doctors will check their liver fat, diet, and do blood tests.
Canada - recruiting
CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome
This study looks at how liver diseases are linked to alcohol or unhealthy eating habits. Researchers want to understand why some people develop liver cancer, even in early stages, by studying health factors, body scans, and liver samples.
France - recruiting
European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)
This study is gathering information about a liver condition called Non-Alcoholic Fatty Liver Disease (NAFLD) in children across Europe. Doctors and scientists are working together to understand it better, find new treatments, and see how it develops over time in young people.
Netherlands · United Kingdom - authorisedTherapeutic exploratory (Phase II)
Randomized, double-blind and multicentric study to assess the efficiency, security and tolerability of the faecal microbiota transfer in capsule form vs. placebo for the treatment of patients with non-alcoholic steatohepatitis (EMOTION)
This study is looking at a new pill made from healthy gut bacteria for people with a liver condition called NASH. It compares this pill to a dummy pill to see if it makes a difference to their liver health and is safe to use.
Spain - recruiting
Integrated Diagnostics for Early Diagnosis of Liver Disease
This study aims to find better ways to spot liver disease early, especially scarring (fibrosis). Researchers are looking at blood tests, gut bacteria, and other information from patients in local clinics. They hope to create a new, improved test that's more accurate than current methods.
United Kingdom